Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | TLR2 | O60603 | 13/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22398651 | 0.94 | MEN1 (0.47) | MEN1KMT2ACA2TLR2CYP2D6 | |
| SCHEMBL22398650 | 0.94 | MEN1 (0.47) | MEN1KMT2ACA2TLR2CYP2D6 | |
| SCHEMBL31756841 | 0.87 | PLK1 (0.42) | MEN1KMT2ACA2TLR2PLK1 | |
| SCHEMBL26232048 | 0.87 | PLK1 (0.42) | MEN1KMT2ACA2TLR2PLK1 | |
| SCHEMBL29131983 | 0.87 | PLK1 (0.42) | MEN1KMT2ACA2TLR2PLK1 | |
| SCHEMBL22398630 | 0.84 | MEN1 (0.41) | MEN1KMT2ACA2TLR2SUCNR1 | |
| SCHEMBL22398629 | 0.84 | MEN1 (0.41) | MEN1KMT2ACA2TLR2SUCNR1 | |
| SCHEMBL18906348 | 0.82 | MEN1 (0.39) | MEN1KMT2ACA2TLR2SUCNR1 | |
| SCHEMBL18906341 | 0.82 | MEN1 (0.39) | MEN1KMT2ACA2TLR2SUCNR1 | |
| SCHEMBL29430501 | 0.81 | MEN1 (0.49) | MEN1KMT2ACA2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3965891-A1 | ANTIBODY DRUG CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | MEN1 2117/4885KMT2A 3057/4885CA2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.